
Retracted 11.11.2019To reduce the overall cardiovascular risk it is advisable to use a combination of drugs - the poly-pill that will increase the effectiveness of therapy and patient compliance. The company «Gedeon Richter» has created a polypill - the Ekvamer medication, which in addition to amlodipine and lisinopril includes rosuvastatin - one of the most powerful and safe statins to date that will provide hosting and primary and secondary prevention of cardiovascular diseases and their complications.
therapy effectiveness, эквамер, cardiovascular risks, ekvamer, compliance, сердечно-сосудистый риск, RC666-701, Diseases of the circulatory (Cardiovascular) system, эффективность терапии, комплаенс, полипилюля, polypill
therapy effectiveness, эквамер, cardiovascular risks, ekvamer, compliance, сердечно-сосудистый риск, RC666-701, Diseases of the circulatory (Cardiovascular) system, эффективность терапии, комплаенс, полипилюля, polypill
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
